<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PMJ</journal-id>
<journal-id journal-id-type="hwp">sppmj</journal-id>
<journal-id journal-id-type="nlm-ta">Palliat Med</journal-id>
<journal-title>Palliative Medicine</journal-title>
<issn pub-type="ppub">0269-2163</issn>
<issn pub-type="epub">1477-030X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269216312464263</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269216312464263</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Off-label prescribing in palliative care – a cross-sectional national survey of Palliative Medicine doctors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>To</surname><given-names>Timothy HM</given-names></name>
<aff id="aff1-0269216312464263">Discipline, Palliative &amp; Supportive Services, Flinders University, Adelaide, Australia; Southern Adelaide Palliative Services; Department of Rehabilitation &amp; Aged Care, Repatriation General Hospital, Adelaide, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Agar</surname><given-names>Meera</given-names></name>
<aff id="aff2-0269216312464263">Palliative Care, Braeside Hospital, New South Wales, Australia; Discipline, Palliative and Supportive Services, Flinders University, Adelaide, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Shelby-James</surname><given-names>Tania</given-names></name>
<aff id="aff3-0269216312464263">Flinders Prevention, Promotion and Primary Health Care, General Practice, Flinders University, Adelaide, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Abernethy</surname><given-names>Amy P</given-names></name>
<aff id="aff4-0269216312464263">Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Discipline, Palliative &amp; Supportive Services, Flinders University, Adelaide, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Doogue</surname><given-names>Matthew</given-names></name>
<aff id="aff5-0269216312464263">Department of Clinical Pharmacology, Flinders Medical Centre, Adelaide, Australia; Discipline Clinical Pharmacology, Flinders University, Adelaide, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Rowett</surname><given-names>Debra</given-names></name>
<aff id="aff6-0269216312464263">Drug and Therapeutic Information Service, Repatriation General Hospital, Adelaide, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Ko</surname><given-names>Danielle</given-names></name>
<aff id="aff7-0269216312464263">Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Currow</surname><given-names>David C</given-names></name>
<aff id="aff8-0269216312464263">Discipline, Palliative &amp; Supportive Services, Flinders University, Adelaide, Australia</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269216312464263">Timothy HM To, Department of Rehabilitation &amp; Aged Care, Repatriation General Hospital, Daw Park, SA 5041, Australia. Email: <email>timothy.to@health.sa.gov.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>4</issue>
<fpage>320</fpage>
<lpage>328</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0269216312464263">
<title>Background:</title>
<p>Regulatory bodies including the European Medicines Agency register medications (formulation, route of administration) for specific clinical indications. Once registered, prescription is at clinicians’ discretion. Off-label use is beyond the registered use. While off-label prescribing may, at times, be appropriate, efficacy and toxicity data are often lacking.</p>
</sec>
<sec id="section2-0269216312464263">
<title>Aim:</title>
<p>The aim of this study was to document off-label use policies (including disclosure and consent) in Australian palliative care units and current practices by palliative care clinicians.</p>
</sec>
<sec id="section3-0269216312464263">
<title>Design:</title>
<p>A national, cross-sectional survey was conducted online following an invitation letter. The survey asked clinicians their most frequent off-label medication/indication dyads and unit policies. Dyads were classified into unregistered, off-label and on-label, and for the latter, whether medications were nationally subsidised.</p>
</sec>
<sec id="section4-0269216312464263">
<title>Setting/participants:</title>
<p>All Australian palliative medicine Fellows and advanced trainees.</p>
</sec>
<sec id="section5-0269216312464263">
<title>Results:</title>
<p>Overall, 105 clinicians responded (53% response rate). The majority did not have policies on off-label medications, and documented consent rarely. In all, 236 medication/indication dyads for 36 medications were noted: 45 dyads (19%) were for two unregistered medications, 118 dyads (50%) were for 26 off-label medications and 73 dyads (31%) were for 12 on-label medications.</p>
</sec>
<sec id="section6-0269216312464263">
<title>Conclusions:</title>
<p>Off-label prescribing with its clinical, legal and ethical implications is common yet poorly recognised by clinicians. A distinction needs to be made between where quality evidence exists but registration has not been updated by the pharmaceutical sponsor and the evidence has not been generated. Further research is required to quantify any iatrogenic harm from off-label prescribing in palliative care.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Off-label prescribing</kwd>
<kwd>palliative care</kwd>
<kwd>drug regulation</kwd>
<kwd>physician knowledge</kwd>
<kwd>iatrogenic harm</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section7-0269216312464263" sec-type="intro">
<title>Introduction</title>
<p>In Australia, the Therapeutic Goods Administration (TGA) has a similar role to the European Medicines Agency (EMEA) in Europe and Food and Drug Administration (FDA) in the United States in registering <italic>medications</italic> (formulation, strength and route of administration) for specific <italic>indications</italic> (population and disease). However, once the medication has been approved, the clinician prescribes and may choose to use the medication in an <italic>off-label</italic> (unlicensed) manner, that is, an unapproved dose, route of administration and/or indication. This is distinct from an <italic>unregistered medication</italic> that is not approved by the regulatory authorities for any indication in their jurisdiction.</p>
<p>Off-label prescribing occurs in three contexts in clinical practice:<sup><xref ref-type="bibr" rid="bibr1-0269216312464263">1</xref></sup></p>
<list id="list1-0269216312464263" list-type="order">
<list-item><p>When approval does not extend to cover the particular dose or indication, although evidence of efficacy is available – often because evidence became available after the medication was registered or after patent has expired, and the label has not been updated;</p></list-item>
<list-item><p>In areas of medicine where high-level evidence is difficult to generate, even for treatments, which are likely to be effective, or because there is a lack of a commercial imperative, for example, rare diseases where adequately powered clinical trials are impossible, or new indications for medications are now out of patent. In these situations, there may be compelling biological plausibility and/or lower level evidence to support prescribing; or</p></list-item>
<list-item><p>When the medication is proven to be ineffective or there is no reason to believe, it is effective.</p></list-item></list>
<p>Off-label prescribing is prevalent in many fields of medicine including general medicine,<sup><xref ref-type="bibr" rid="bibr2-0269216312464263">2</xref></sup> psychiatry,<sup><xref ref-type="bibr" rid="bibr3-0269216312464263">3</xref></sup> obstetrics,<sup><xref ref-type="bibr" rid="bibr4-0269216312464263">4</xref></sup> paediatrics,<sup><xref ref-type="bibr" rid="bibr5-0269216312464263">5</xref><xref ref-type="bibr" rid="bibr6-0269216312464263"/>–<xref ref-type="bibr" rid="bibr7-0269216312464263">7</xref></sup> oncology,<sup><xref ref-type="bibr" rid="bibr8-0269216312464263">8</xref><xref ref-type="bibr" rid="bibr9-0269216312464263"/>–<xref ref-type="bibr" rid="bibr10-0269216312464263">10</xref></sup> HIV/AIDS<sup><xref ref-type="bibr" rid="bibr11-0269216312464263">11</xref></sup> and palliative care.<sup><xref ref-type="bibr" rid="bibr12-0269216312464263">12</xref>,<xref ref-type="bibr" rid="bibr13-0269216312464263">13</xref></sup> Off-label prescribing is best documented in paediatrics, with prevalence of 11% in general practice, 72% in a neonatal intensive care unit<sup><xref ref-type="bibr" rid="bibr5-0269216312464263">5</xref>,<xref ref-type="bibr" rid="bibr14-0269216312464263">14</xref>,<xref ref-type="bibr" rid="bibr15-0269216312464263">15</xref></sup> and up to 89% of paediatric inpatients.<sup><xref ref-type="bibr" rid="bibr16-0269216312464263">16</xref></sup> In other populations, estimates of off-label prescribing vary: 8% in psychiatry inpatients,<sup><xref ref-type="bibr" rid="bibr3-0269216312464263">3</xref></sup> 21% in office-based physicians,<sup><xref ref-type="bibr" rid="bibr2-0269216312464263">2</xref></sup> 40% in HIV patients,<sup><xref ref-type="bibr" rid="bibr11-0269216312464263">11</xref></sup> and up to 65% in oncology patients.<sup><xref ref-type="bibr" rid="bibr10-0269216312464263">10</xref>,<xref ref-type="bibr" rid="bibr17-0269216312464263">17</xref>,<xref ref-type="bibr" rid="bibr18-0269216312464263">18</xref></sup></p>
<p>In palliative care, patients often have multiple pathologies and complex symptoms, are frequently on multiple medications<sup><xref ref-type="bibr" rid="bibr19-0269216312464263">19</xref></sup> and have fragile and rapidly changing health states. Adequately designed clinical trials in this population are feasible but challenging. Consequently, many medications used in palliative care are prescribed off-label in a setting where drug–host and drug–drug interactions<sup><xref ref-type="bibr" rid="bibr20-0269216312464263">20</xref></sup> are already likely. Patients may also have limited ability to provide informed consent for off-label medications.<sup><xref ref-type="bibr" rid="bibr21-0269216312464263">21</xref></sup></p>
<p>Pavis and Wilcock<sup><xref ref-type="bibr" rid="bibr13-0269216312464263">13</xref></sup> examined the off-label use of medications in palliative care in the United Kingdom in 2001 against General Medical Council (GMC) recommendations, finding low rates of verbal or written consent and poor documentation of reasons for off-label use in case notes. While these GMC recommendations have since been updated,<sup><xref ref-type="bibr" rid="bibr22-0269216312464263">22</xref></sup> the questions asked by Pavis and Wilcock remain pertinent to quality prescribing. The aim of this study was to examine off-label prescribing in Australian palliative medicine clinicians through a national point prevalence survey.</p>
</sec>
<sec id="section8-0269216312464263" sec-type="methods">
<title>Methods</title>
<sec id="section9-0269216312464263">
<title>Study setting</title>
<p>Specialist palliative care services (SPCS) in Australia span a range of different service delivery models, from large regional multidisciplinary teams to single clinical nurses in small rural locations. SPCS may include public and private hospitals with inpatient and/or consultative services, free-standing palliative care units, outpatient clinics and community care teams. SPCS may be the primary health provider but more commonly work in consultation to support general practitioners, other specialists and community services.</p>
</sec>
<sec id="section10-0269216312464263">
<title>Study design and participants</title>
<p>This cross-sectional study was part of a larger survey looking at prescribing practices. The survey included participants’ demographics, scopes of palliative medicine practice, level of experience, and perceptions and experience of off-label prescribing for the three medications in each respondent’s practice that he/she most often used off-label (<xref ref-type="app" rid="app1-0269216312464263">Appendix 1</xref>).</p>
<p>An invitation to participate, with a printed version of the survey, was sent in July 2010 to all Australian-based members of the Australia and New Zealand Society of Palliative Medicine (ANZSPM), a medical society open to doctors with an interest in palliative medicine. The letter included a link to the online survey.</p>
</sec>
<sec id="section11-0269216312464263">
<title>Data collection</title>
<p>Survey data were entered by participants using the online survey tool, or if completed on paper were entered by an administrative assistant.</p>
</sec>
<sec id="section12-0269216312464263">
<title>Data analysis</title>
<p>Medication registration and listed indications were obtained from the Australian TGA website (<ext-link ext-link-type="uri" xlink:href="http://www.tga.gov.au">www.tga.gov.au</ext-link>, accessed 9<sup>th</sup> August 2011). All nominated medication/indication dyads were classified as unregistered, off-label or on-label. In Australia, while the TGA regulates medication approval, the Pharmaceutical Benefits Scheme (PBS) determines medication subsidy, that is, medications approved by the TGA do not automatically receive subsidy from the PBS, and if not, patients must pay full price. Given this distinction and the potential to misconstrue on-label but unsubsidised dyads as off-label, on-label dyads were also grouped into subsidised and unsubsidised (www.pbs.gov.au, accessed 9<sup>th</sup> August 2011). Uncertainty in interpretation of listed indications were reviewed by the authors and consensus reached. As the TGA consider any medication registered for parenteral use can be given intravenously, intramuscularly or subcutaneously if administerable without dilution, route of administration was not considered separately in the analysis. Nominated indications by survey respondents were grouped for the purpose of analysis (e.g. nausea/vomiting, pain and delirium/agitation).</p>
<p>Data were analysed using PASW 18.0 (SPSS Corp. Inc., 2008. Chicago, IL. USA). Descriptive statistics were used to analyse categorical variables, and comparisons were done using Chi-square test or Fisher’s exact test as appropriate.</p>
<p>The reporting of this survey complies with strengthening the reporting of observational studies in epidemiology (STROBE) criteria for reporting cross-sectional studies.<sup><xref ref-type="bibr" rid="bibr23-0269216312464263">23</xref></sup> Ethical approval for this study was granted by the Flinders University Social and Behavioural Research Ethics Committee.</p>
</sec>
</sec>
<sec id="section13-0269216312464263" sec-type="results">
<title>Results</title>
<p>In July 2010, 213 of 220 registered Australian and New Zealand Society of Palliative Medicine (ANZSPM) members had a valid contact address, and of these, 105 (49%) provided valid responses for analysis. Thirty-nine percent were male and more than 74% of the respondents were older than 40 years. The majority had been practising medicine for more than 10 years (91%), and palliative medicine for more than 5 years (78%). Respondents worked in a variety of settings: acute inpatient (35%), hospital liaison (64%), community (46%), outpatient (46%) and palliative care unit (55%). Most respondents (91%) saw more than 60 new patients per year.</p>
<p>The majority of respondents reported that their services did not have, or were unaware of, a policy on providing information to patients about the off-label use of medications (89%), nor consistently limited the use of off-label use of medications to consultants (70%). The documentation of consent, verbal or written, was variable but tended to be absent or inconsistent (<xref ref-type="table" rid="table1-0269216312464263">Table 1</xref>). When asked to quantify the number of occasions verbal or written consent was obtained, or reasons documented in the notes, the number of occasions reported was frequently much lower than expected given the numbers of patients seen (<xref ref-type="table" rid="table2-0269216312464263">Table 2</xref>). For example, eight of the ten respondents who reported always documenting reasons for off-label prescribing saw more than 100 patients per year with life-limiting illnesses. However, when asked to quantify consent and documentation, only 7 gave a count of verbal or written consent, with 6 of the 7 reporting 10 or less occasions; furthermore, all the five respondents who gave a count of documenting in the notes reported this 10 or less times. Overall, 20% of respondents never obtained verbal nor written consent, nor documented a reason for off-label use.</p>
<table-wrap id="table1-0269216312464263" position="float">
<label>Table 1.</label>
<caption>
<p>Respondents’ practices regarding off-label prescribing and associated verbal or written consent, and documentation of reasons.</p>
</caption>
<graphic alternate-form-of="table1-0269216312464263" xlink:href="10.1177_0269216312464263-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Always (%)</th>
<th align="left">Sometimes (%)</th>
<th align="left">Never (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you limit off-label prescribing to consultants only?</td>
<td>29 (29)</td>
<td>39 (39)</td>
<td>31 (31)</td>
</tr>
<tr>
<td>Do you obtain verbal consent from the patient/caregiver?</td>
<td>24 (24)</td>
<td>49 (50)</td>
<td>26 (26)</td>
</tr>
<tr>
<td>Do you obtain written consent from the patient/caregiver?</td>
<td>1 (1)</td>
<td>23 (24)</td>
<td>74 (76)</td>
</tr>
<tr>
<td>Do you document in your notes when prescribing off-label and the reasons for this?</td>
<td>10 (10)</td>
<td>38 (39)</td>
<td>49 (51)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-0269216312464263" position="float">
<label>Table 2.</label>
<caption>
<p>Number of occasions of verbal or written informed consent, and documentation of the reason in the notes for off-label prescribing in the last 6 months.</p>
</caption>
<graphic alternate-form-of="table2-0269216312464263" xlink:href="10.1177_0269216312464263-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Number of occasions</th>
<th align="left">Verbal or written consent<sup><xref ref-type="table-fn" rid="table-fn1-0269216312464263">a</xref></sup> <italic>n</italic> = 67</th>
<th align="left">Documentation in notes<sup><xref ref-type="table-fn" rid="table-fn2-0269216312464263">b</xref></sup> <italic>n</italic> = 54</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>18 (27%)</td>
<td>23 (43%)</td>
</tr>
<tr>
<td>1–5</td>
<td>17 (25%)</td>
<td>18 (33%)</td>
</tr>
<tr>
<td>6–10</td>
<td>17 (25%)</td>
<td>10 (19%)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>15 (22%)</td>
<td>3 (6%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269216312464263">
<label>a</label>
<p>Of the 105, 38 (36%) had no response</p></fn>
<fn id="table-fn2-0269216312464263">
<label>b</label>
<p>Of the 105, 51 (49%) had no response</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The 105 respondents proposed 236 off-label medication/indication dyads for 36 medications (<xref ref-type="fig" rid="fig1-0269216312464263">Figure 1</xref>, <xref ref-type="table" rid="table3-0269216312464263">Table 3</xref>). Forty-five (19%) dyads for two medications were unregistered (cyclizine and levomepromazine (methotrimeprazine) are not registered in Australia). A total of 118 (50%) dyads were off-label, covering 26 medications for 38 indications. The remaining 73 (31%) dyads were on-label, covering 12 medications for 14 indications. Of these 73 on-label dyads, 31 were of pregabalin or gabapentin for pain, which are registered but not subsidised indications (off-subsidy use).</p>
<fig id="fig1-0269216312464263" position="float">
<label>Figure 1.</label>
<caption>
<p>Nominated medication/indication dyads categorised by unregistered, off-label and on-label (<italic>n</italic> = 236).</p>
</caption>
<graphic xlink:href="10.1177_0269216312464263-fig1.tif"/></fig>
<table-wrap id="table3-0269216312464263" position="float">
<label>Table 3.</label>
<caption><p>Top nominated medication/indication dyads categorised by unregistered medication, off-label use and on-label use.</p></caption>
<graphic alternate-form-of="table3-0269216312464263" xlink:href="10.1177_0269216312464263-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Unregistered</th>
<th align="left">Indication</th>
<th align="left"><italic>n</italic></th>
<th align="left">Off-label</th>
<th align="left">Indication</th>
<th align="left"><italic>n</italic></th>
<th align="left">On-label</th>
<th align="left">Indication</th>
<th align="left"><italic>n</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Levomepromazine</td>
<td>Nausea/vomiting</td>
<td>19</td>
<td>Ketamine</td>
<td>Pain</td>
<td>24</td>
<td>Haloperidol</td>
<td>Nausea/vomiting</td>
<td>22</td>
</tr>
<tr>
<td/>
<td>Delirium/agitation</td>
<td>2</td>
<td>Octreotide</td>
<td>Malignant bowel obstruction</td>
<td>20</td>
<td>Gabapentin</td>
<td>Pain</td>
<td>19</td>
</tr>
<tr>
<td/>
<td>Sedation</td>
<td>1</td>
<td/>
<td>Nausea/vomiting</td>
<td>2</td>
<td>Pregabalin</td>
<td>Pain</td>
<td>12</td>
</tr>
<tr>
<td/>
<td>Dyspnoea</td>
<td>1</td>
<td>Clonazepam</td>
<td>Delirium/agitation</td>
<td>7</td>
<td>Midazolam</td>
<td>Sedation</td>
<td>4</td>
</tr>
<tr>
<td/>
<td>Blank</td>
<td>1</td>
<td/>
<td>Sedation</td>
<td>6</td>
<td/>
<td>Agitation</td>
<td>2</td>
</tr>
<tr>
<td>Cyclizine</td>
<td>Nausea/vomiting</td>
<td>19</td>
<td/>
<td>Anxiety</td>
<td>3</td>
<td>Metoclopramide</td>
<td>Nausea/vomiting</td>
<td>5</td>
</tr>
<tr>
<td/>
<td>Malignant bowel obstruction</td>
<td>1</td>
<td/>
<td>Pain</td>
<td>2</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td>Blank</td>
<td>1</td>
<td/>
<td>Distress</td>
<td>1</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>Olanzapine</td>
<td>Delirium/agitation</td>
<td>5</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Nausea/vomiting</td>
<td>3</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>Midazolam</td>
<td>Anxiety</td>
<td>4</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Dyspnoea</td>
<td>2</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Pain</td>
<td>1</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>Morphine</td>
<td>Dyspnoea</td>
<td>6</td>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section14-0269216312464263" sec-type="discussion">
<title>Discussion</title>
<p>This study has found that palliative care practitioners have a poor understanding of medication regulations and the status of frequently used medications. When asked about ‘licensed drugs for unlicensed uses’, only 50% of nominated medication/indication dyads were correct.</p>
<p>Nineteen percent of the dyads were unregistered. Previous registration for cyclizine and levomepromazine has expired, and given their limited general use and low commercial value, their sponsors have declined to update and renew their registration. However, these medications are available in Australia using the Special Access Scheme, allowing importation of unregistered medications.</p>
<p>The remaining 31% dyads were on-label. Respondents may have mistaken on-label but unsubsidised medications with off-label use. Furthermore, a number of nominated dyads may have been designated off-label because the route (e.g. subcutaneous) was believed to be off-label. This reflects poor understanding of medication regulation processes that lead to a medication being off-label.</p>
<p>This poor understanding may be, in part, due to a widespread lack of service policies to guide off-label prescribing. Only 11% of respondents reported that their service had policies for the use of off-label medications; however, this was more than British palliative care services (2%) a decade ago<sup><xref ref-type="bibr" rid="bibr13-0269216312464263">13</xref></sup> but less than American academic medical centres (17%)<sup><xref ref-type="bibr" rid="bibr24-0269216312464263">24</xref></sup> and Italian hospices (28%)<sup><xref ref-type="bibr" rid="bibr25-0269216312464263">25</xref></sup> The practices for off-label prescribing are reportedly better than in Pavis and Wilcock’s<sup><xref ref-type="bibr" rid="bibr13-0269216312464263">13</xref></sup> study, with 26% of respondents in this study never seeking verbal consent (compared with 38%) and 76% never seeking written consent (compared with 93%), though never documenting reasons still occurred in approximately 50% of cases.<sup><xref ref-type="bibr" rid="bibr13-0269216312464263">13</xref></sup> While there may have been some improvement in practices around off-label prescribing since 2001, this survey demonstrates there are still large deficits, though 100% compliance may not be necessary.<sup><xref ref-type="bibr" rid="bibr22-0269216312464263">22</xref></sup> Establishing a robust policy is a first step, but compliance with these policies is likely to be extremely limited, given responses reflected into this survey.</p>
<sec id="section15-0269216312464263">
<title>What are the issues around off-label prescribing?</title>
<sec id="section16-0269216312464263">
<title>Clinically</title>
<p>Off-label prescribing is not a new issue.<sup><xref ref-type="bibr" rid="bibr26-0269216312464263">26</xref>,<xref ref-type="bibr" rid="bibr27-0269216312464263">27</xref></sup> While some cases of off-label prescribing is clinically appropriate, studies have demonstrated that off-label prescribing</p>
<list id="list2-0269216312464263" list-type="simple"><list-item><p>is poorly recognised,<sup><xref ref-type="bibr" rid="bibr28-0269216312464263">28</xref></sup></p></list-item>
<list-item><p>may lack adequate informed consent processes,<sup><xref ref-type="bibr" rid="bibr29-0269216312464263">29</xref>,<xref ref-type="bibr" rid="bibr30-0269216312464263">30</xref></sup></p></list-item>
<list-item><p>lacks the efficacy achieved in on-label prescribing,<sup><xref ref-type="bibr" rid="bibr31-0269216312464263">31</xref>,<xref ref-type="bibr" rid="bibr32-0269216312464263">32</xref></sup> and</p></list-item>
<list-item><p>is more likely to be associated with increased or unrecognised adverse events.<sup><xref ref-type="bibr" rid="bibr33-0269216312464263">33</xref><xref ref-type="bibr" rid="bibr34-0269216312464263"/>–<xref ref-type="bibr" rid="bibr35-0269216312464263">35</xref></sup></p></list-item></list>
<p>While off-label prescribing may have benefits, these must be weighed against harms to define the net clinical effect.</p>
</sec>
<sec id="section17-0269216312464263">
<title>Ethically</title>
<p>The community reasonably expects that prescribing will be for indications approved by reputable regulatory authorities, supported by high-quality evidence, and any deviation from this will be supported by robust policy and informed consent.<sup><xref ref-type="bibr" rid="bibr36-0269216312464263">36</xref></sup> Off-label medication use may blur the distinction between clinical practice and experimentation, creating significant ethical concerns.<sup><xref ref-type="bibr" rid="bibr37-0269216312464263">37</xref></sup> Prescribers must understand the potential harms and benefits of a particular therapy (including uncertainties), any alternative therapeutic options and facilitate informed shared decision-making with the patient.</p>
</sec>
<sec id="section18-0269216312464263">
<title>Legally</title>
<p>Once a medication is registered, off-label use is a matter of medical judgement, shifting the focus of ethical and legal responsibility (and hence liability) from manufacturers/suppliers to the prescribing practitioner.<sup><xref ref-type="bibr" rid="bibr1-0269216312464263">1</xref>,<xref ref-type="bibr" rid="bibr38-0269216312464263">38</xref>,<xref ref-type="bibr" rid="bibr39-0269216312464263">39</xref></sup> Prescribing off-label is not <italic>prima facie</italic> evidence of medical negligence – negligence requires that the off-label use of the medication for the particular patient was not in line with a reasonable standard of medical care.<sup><xref ref-type="bibr" rid="bibr40-0269216312464263">40</xref></sup> Regulations prohibit the promotion of off-label uses of medications; however, historically there has been omission or understating of risks, of overstating effectiveness and of unjustifiable comparative claims for off-label medication use.<sup><xref ref-type="bibr" rid="bibr41-0269216312464263">41</xref><xref ref-type="bibr" rid="bibr42-0269216312464263"/>–<xref ref-type="bibr" rid="bibr43-0269216312464263">43</xref></sup></p>
</sec>
</sec>
<sec id="section19-0269216312464263">
<title>Why does off-label prescribing exist?</title>
<p>The TGA, EMEA and FDA regulate prescription medication marketing, not clinician nor institutional prescribing.<sup><xref ref-type="bibr" rid="bibr28-0269216312464263">28</xref>,<xref ref-type="bibr" rid="bibr43-0269216312464263">43</xref></sup> Given the substantial resources required and evidence base needed to register a medication or update its indications, there will always be off-label prescribing.<sup><xref ref-type="bibr" rid="bibr44-0269216312464263">44</xref></sup> In some cases, this is supported by studies that underpin particular off-label indications, but regulatory approval has not been sought to cover the indication, dose or route of administration.<sup><xref ref-type="bibr" rid="bibr29-0269216312464263">29</xref>,<xref ref-type="bibr" rid="bibr45-0269216312464263">45</xref></sup></p>
<p>There are examples where off-label uses of medications have provided patients with improved outcomes, or where such prescribing genuinely reflects leading edge clinical care.<sup><xref ref-type="bibr" rid="bibr46-0269216312464263">46</xref></sup> Often this is where off-label prescribing was biologically plausible and supported by clinical evidence, although for yet unregistered indications. Examples include imatinib for gastrointestinal stromal tumours,<sup><xref ref-type="bibr" rid="bibr47-0269216312464263">47</xref></sup> morphine for dyspnoea<sup><xref ref-type="bibr" rid="bibr48-0269216312464263">48</xref></sup> and immunomodulators in chronic autoimmune/inflammatory conditions.</p>
<p>Expanding indications, or ‘indication creep’, may provide important therapeutic efficacy data; however, measuring net clinical effect requires systematic assessment of benefits and harms.<sup><xref ref-type="bibr" rid="bibr49-0269216312464263">49</xref>,<xref ref-type="bibr" rid="bibr50-0269216312464263">50</xref></sup> The risk is that practitioners expand indications with limited scientific rationale while the pharmaceutical industry either passively observes broadening indications or actively promotes off-label use even in the absence of evidence of efficacy and safety.<sup><xref ref-type="bibr" rid="bibr50-0269216312464263">50</xref></sup></p>
<p>Prescribing is strongly influenced by local practice, anecdote or expert opinion, which may not always reflect best evidence.<sup><xref ref-type="bibr" rid="bibr51-0269216312464263">51</xref>,<xref ref-type="bibr" rid="bibr52-0269216312464263">52</xref></sup> A study of American office-based physicians found that 73% of off-label prescribing had little or no scientific support.<sup><xref ref-type="bibr" rid="bibr2-0269216312464263">2</xref></sup> Furthermore, as demonstrated in this study, many practitioners do not know whether they are working with registered indications, even in their area of specialty practice.<sup><xref ref-type="bibr" rid="bibr28-0269216312464263">28</xref></sup></p>
</sec>
<sec id="section20-0269216312464263">
<title>Off-label prescribing in palliative care?</title>
<p>The available literature on off-label prescribing in palliative care suggests that 12%–26% of prescriptions are off-label,<sup><xref ref-type="bibr" rid="bibr12-0269216312464263">12</xref>,<xref ref-type="bibr" rid="bibr25-0269216312464263">25</xref>,<xref ref-type="bibr" rid="bibr53-0269216312464263">53</xref></sup> with low rates of system-level strategies to address off-label prescribing.<sup><xref ref-type="bibr" rid="bibr25-0269216312464263">25</xref></sup> Off-label prescribing may be biologically plausible, as with octreotide for malignant bowel obstruction, or supported by high-level evidence, as in the case of morphine for dyspnoea.</p>
<p>A number of factors have hindered the building of an evidence base for prescribing in palliative care. This population is often considered difficult to study, due to declining and unstable health, comorbidities, cognitive dysfunction and ‘gate-keeping’ to ‘protect’ patients from clinical trials perceived too burdensome despite patient and caregiver support.<sup><xref ref-type="bibr" rid="bibr54-0269216312464263">54</xref><xref ref-type="bibr" rid="bibr55-0269216312464263"/>—<xref ref-type="bibr" rid="bibr56-0269216312464263">56</xref></sup> Many of the medications commonly used in palliative care are off patent, and thus, there is little incentive for further research or to expand registration when definitive studies emerge.</p>
<sec id="section21-0269216312464263">
<title>Limitations</title>
<p>This study relies on self-report with no easy way to provide third-party verification of the data presented. Furthermore, given the demonstrated poor understanding of off-label prescribing, respondents’ self-report may not reflect the extent of their off-label prescribing and are likely to underestimate the prevalence. Furthermore, the sample may be biased, with respondents potentially those most conscious of issues surrounding off-label use, and therefore, the estimates are a more positive picture than the day-to-day reality. Without accurate quantification of the prevalence of off-label prescribing, the interpretation of these data is limited.</p>
</sec>
<sec id="section22-0269216312464263">
<title>Implications for practice</title>
<p>Ethical off-label use requires at least one of the following:</p>
<list id="list3-0269216312464263" list-type="simple">
<list-item><p>existing high-level evidence,</p></list-item>
<list-item><p>the setting of a properly designed rigorous clinical trial or</p></list-item>
<list-item><p>exceptional use justified by individual clinical circumstances.<sup><xref ref-type="bibr" rid="bibr29-0269216312464263">29</xref></sup></p></list-item>
</list>
<p>To evaluate the appropriateness of off-label medication use, proposed frameworks consider the level of evidence available and give guidance as to the level of consent, pharmacovigilance and ongoing review required (<xref ref-type="fig" rid="fig2-0269216312464263">Figure 2</xref>).<sup><xref ref-type="bibr" rid="bibr22-0269216312464263">22</xref>,<xref ref-type="bibr" rid="bibr29-0269216312464263">29</xref>,<xref ref-type="bibr" rid="bibr37-0269216312464263">37</xref>,<xref ref-type="bibr" rid="bibr57-0269216312464263">57</xref></sup> As with any treatment decision, but especially pertinent in cases with low certainty of net clinical effect, a process of shared decision-making with the patient is required. This should include disclosure of the nature of off-label use, the benefits and harms, the evidence to support the off-label use and why in the particular patient’s circumstances, the prescriber believes there is no equivalent or better TGA/EMEA-approved alternative.<sup><xref ref-type="bibr" rid="bibr36-0269216312464263">36</xref>,<xref ref-type="bibr" rid="bibr57-0269216312464263">57</xref></sup> This should be supported by documentation of the informed consent process and discussion in the medical notes.<sup><xref ref-type="bibr" rid="bibr57-0269216312464263">57</xref>,<xref ref-type="bibr" rid="bibr58-0269216312464263">58</xref></sup></p>
<fig id="fig2-0269216312464263" position="float">
<label>Figure 2.</label>
<caption>
<p>Assessing appropriateness of off-label medicines use.<sup><xref ref-type="bibr" rid="bibr29-0269216312464263">29</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_0269216312464263-fig2.tif"/></fig>
<p>Given the uncertainties of benefits or harms, there is a need to specify treatment goals and to monitor net clinical effect at intervals determined by expected time to response, and requirements for medication titration.<sup><xref ref-type="bibr" rid="bibr44-0269216312464263">44</xref>,<xref ref-type="bibr" rid="bibr59-0269216312464263">59</xref>,<xref ref-type="bibr" rid="bibr60-0269216312464263">60</xref></sup> Ideally, formal review of efficacy, safety and cost outcomes should occur to guide further practice.<sup><xref ref-type="bibr" rid="bibr37-0269216312464263">37</xref></sup> As a minimum, prospective data should be collected on the net clinical effects of the off-label use of medications, and such data aggregated.<sup><xref ref-type="bibr" rid="bibr61-0269216312464263">61</xref></sup></p>
<p>While changing clinician behaviour can be difficult,<sup><xref ref-type="bibr" rid="bibr51-0269216312464263">51</xref></sup> provision of valid evidence and interventions targeting prescribing have been shown to change clinician understanding and prescribing behaviour.<sup><xref ref-type="bibr" rid="bibr50-0269216312464263">50</xref>,<xref ref-type="bibr" rid="bibr62-0269216312464263">62</xref></sup> Other potential strategies include requiring the primary indication when prescribing, which would facilitate post-marketing surveillance.<sup><xref ref-type="bibr" rid="bibr63-0269216312464263">63</xref></sup> Reducing administrative and financial barriers to approving new indications for registered medications would remove key obstacles to updating registration without lessening the level of evidence required. Professional and regulatory bodies can also guide health policy and influence clinician prescribing.<sup><xref ref-type="bibr" rid="bibr57-0269216312464263">57</xref></sup> The role of the pharmaceutical industry in promoting off-label prescribing has become more widely recognised in recent cases such as gabapentin,<sup><xref ref-type="bibr" rid="bibr64-0269216312464263">64</xref></sup> oxycodone<sup><xref ref-type="bibr" rid="bibr65-0269216312464263">65</xref></sup> and erythropoietin,<sup><xref ref-type="bibr" rid="bibr66-0269216312464263">66</xref></sup> and substantial penalties have been imposed in an attempt to discourage such actions.</p>
</sec>
<sec id="section23-0269216312464263">
<title>Implications for research</title>
<p>A lack of evidence of effect does not equate to evidence of ineffectiveness. There needs to be prioritisation of research to improve the evidence for medications used off-label in palliative care, particularly those used frequently, with high cost, with significant potential benefits and/or harms, or with little supporting evidence.<sup><xref ref-type="bibr" rid="bibr67-0269216312464263">67</xref>,<xref ref-type="bibr" rid="bibr68-0269216312464263">68</xref></sup> Accurate, prospective determination of the prevalence of off-label prescribing in palliative care, and the medications used, will help guide studies to improve the evidence base.</p>
<p>With regular monitoring of prescribing practice, emerging medication/indication dyads can be identified and appropriate studies performed to build an evidence base. At a minimum, pharmacokinetic studies could be performed in healthy volunteers. Ideally comparative effectiveness studies need to be performed to identify efficacy compared to non-pharmacological and on-label options and to systematically address iatrogenic harm, toxicity and cost-effectiveness, giving an indication of net clinical effect. Should a medication/indication dyad prove beneficial, the dyad should be submitted to the regulatory bodies for registration. Ongoing post-registration evaluation of benefits and harms is required to ensure that the medication is performing as expected.</p>
<p>Further work is required on strategies to optimise prescribing practices and to develop policies around off-label use of medications.</p>
</sec>
</sec>
</sec>
<sec id="section24-0269216312464263" sec-type="conclusions">
<title>Conclusion</title>
<p>Off-label prescribing in Australian palliative medicine clinicians is poorly recognised and has clinical, legal and ethical implications for the management of palliative care patients.</p>
<p>Two key questions need to be asked in considering off-label use of medications:</p>
<list id="list4-0269216312464263" list-type="simple"><list-item><p>Does quality evidence exist but registration has not been updated by the pharmaceutical sponsors? and</p></list-item>
<list-item><p>Has the evidence not been generated (or exists and suggests that there is no net clinical benefit)?</p></list-item></list>
<p>For clinicians, categorising the medication under one of these two scenarios will guide appropriateness and level of consent, and this should be complemented with subsequent pharmacovigilance for net clinical effect. For policy makers and funding bodies, medications used off-label where there is insufficient evidence should be targeted for further research with a view to updating registration if subsequent studies demonstrate net clinical benefit. More research is required to determine the prevalence and clinical consequences of off-label prescribing in palliative care and to direct intervention for clinicians and patients.</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-0269216312464263">
<title>Appendix 1</title>
<sec id="section25-0269216312464263">
<title>Survey of the use of licensed drugs for unlicensed uses in palliative care</title>
<graphic id="img1-0269216312464263" position="anchor" xlink:href="10.1177_0269216312464263-img1.tif"/>
</sec>
</app>
</app-group>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that there is no conflict of interest.</p></fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269216312464263">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casali</surname><given-names>PG</given-names></name>
</person-group>. <article-title>The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)</article-title>. <source>Ann Oncol</source> <year>2007</year>; <volume>18</volume>: <fpage>1923</fpage>–<lpage>1925</lpage>.</citation>
</ref>
<ref id="bibr2-0269216312464263">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Radley</surname><given-names>DC</given-names></name>
<name><surname>Finkelstein</surname><given-names>SN</given-names></name>
<name><surname>Stafford</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Off-label prescribing among office-based physicians</article-title>. <source>Arch Intern Med</source> <year>2006</year>; <volume>166</volume>: <fpage>1021</fpage>–<lpage>1026</lpage>.</citation>
</ref>
<ref id="bibr3-0269216312464263">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Douglas-Hall</surname><given-names>P</given-names></name>
<name><surname>Fuller</surname><given-names>A</given-names></name>
<name><surname>Gill-Banham</surname><given-names>S</given-names></name>
</person-group>. <article-title>An analysis of off-licence prescribing in psychiatric medicine</article-title>. <source>Pharm J</source> <year>2001</year>; <volume>267</volume>: <fpage>890</fpage>–<lpage>891</lpage>.</citation>
</ref>
<ref id="bibr4-0269216312464263">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herring</surname><given-names>C</given-names></name>
<name><surname>McManus</surname><given-names>A</given-names></name>
<name><surname>Weeks</surname><given-names>A</given-names></name>
</person-group>. <article-title>Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women’s Hospital</article-title>. <source>Int J Pharm Pract</source> <year>2010</year>; <volume>18</volume>: <fpage>226</fpage>–<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr5-0269216312464263">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McIntyre</surname><given-names>J</given-names></name>
<name><surname>Conroy</surname><given-names>S</given-names></name>
<name><surname>Avery</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Unlicensed and off label prescribing of drugs in general practice</article-title>. <source>Arch Dis Child</source> <year>2000</year>; <volume>83</volume>: <fpage>498</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr6-0269216312464263">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mason</surname><given-names>J</given-names></name>
<name><surname>Pirmohamed</surname><given-names>M</given-names></name>
<name><surname>Nunn</surname><given-names>T</given-names></name>
</person-group>. <article-title>Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature</article-title>. <source>Eur J Clin Pharmacol</source> <year>2012</year>; <volume>68</volume>: <fpage>21</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr7-0269216312464263">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Conroy</surname><given-names>S</given-names></name>
<name><surname>Choonara</surname><given-names>I</given-names></name>
<name><surname>Impicciatore</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children</article-title>. <source>BMJ</source> <year>2000</year>; <volume>320</volume>: <fpage>79</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr8-0269216312464263">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mellor</surname><given-names>JD</given-names></name>
<name><surname>Bensted</surname><given-names>KE</given-names></name>
<name><surname>Chan</surname><given-names>PL</given-names></name>
</person-group>. <article-title>Off label and unlicensed prescribing in a specialist oncology center in Australia</article-title>. <source>Asia-Pacific J of Clin Oncol</source> <year>2009</year>; <volume>5</volume>: <fpage>242</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr9-0269216312464263">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poole</surname><given-names>SG</given-names></name>
<name><surname>Dooley</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Off-label prescribing in oncology</article-title>. <source>Support Care Canc</source> <year>2004</year>; <volume>12</volume>: <fpage>302</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr10-0269216312464263">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abernethy</surname><given-names>AP</given-names></name>
<name><surname>Raman</surname><given-names>G</given-names></name>
<name><surname>Balk</surname><given-names>EM</given-names></name>
<etal/></person-group>. <article-title>Systematic review: reliability of compendia methods for off-label oncology indications</article-title>. <source>Ann Intern Med</source> <year>2009</year>; <volume>150</volume>: <fpage>336</fpage>–<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr11-0269216312464263">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brosgart</surname><given-names>CL</given-names></name>
<name><surname>Mitchell</surname><given-names>T</given-names></name>
<name><surname>Charlebois</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Off-label drug use in human immunodeficiency virus disease</article-title>. <source>J Acquir Immune Defic Syndr Hum Retrovirol</source> <year>1996</year>; <volume>12</volume>: <fpage>56</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr12-0269216312464263">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>CV</given-names></name>
<name><surname>Kirkham</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Unlicensed uses for medication in a palliative care unit</article-title>. <source>Palliat Med</source> <year>1999</year>; <volume>13</volume>: <fpage>145</fpage>–<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr13-0269216312464263">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pavis</surname><given-names>H</given-names></name>
<name><surname>Wilcock</surname><given-names>A</given-names></name>
</person-group>. <article-title>Prescribing of drugs for use outside their licence in palliative care: survey of specialists in the United Kingdom</article-title>. <source>BMJ</source> <year>2001</year>; <volume>323</volume>: <fpage>484</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr14-0269216312464263">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Avenel</surname><given-names>S</given-names></name>
<name><surname>Bomkratz</surname><given-names>A</given-names></name>
<name><surname>Dassieu</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>The incidence of prescriptions without marketing product license in a neonatal intensive care unit</article-title>. <source>Arch Pediatr</source> <year>2000</year>; <volume>7</volume>: <fpage>143</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr15-0269216312464263">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cuzzolin</surname><given-names>L</given-names></name>
<name><surname>Zaccaron</surname><given-names>A</given-names></name>
<name><surname>Fanos</surname><given-names>V</given-names></name>
</person-group>. <article-title>Unlicensed and off-label uses of drugs in paediatrics: a review of the literature</article-title>. <source>Fundam Clin Pharmacol</source> <year>2003</year>; <volume>17</volume>: <fpage>125</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr16-0269216312464263">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pandolfini</surname><given-names>C</given-names></name>
<name><surname>Impicciatore</surname><given-names>P</given-names></name>
<name><surname>Provasi</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Off-label use of drugs in Italy: a prospective, observational and multicentre study</article-title>. <source>Acta Paediatr</source> <year>2002</year>; <volume>91</volume>: <fpage>339</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr17-0269216312464263">
<label>17.</label>
<citation citation-type="journal"><collab>Oncology ASoC</collab>. <article-title>Reimbursement for cancer treatment: coverage of off-label drug indications</article-title>. <source>J Clin Oncol</source> <year>2006</year>; <volume>24</volume>: <fpage>3206</fpage>–<lpage>3208</lpage>.</citation>
</ref>
<ref id="bibr18-0269216312464263">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soares</surname><given-names>M</given-names></name>
</person-group>. <article-title>‘Off-label’ indications for oncology drug use and drug compendia: history and current status</article-title>. <source>J Oncol Pract</source> <year>2005</year>; <volume>1</volume>: <fpage>102</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr19-0269216312464263">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
<name><surname>Stevenson</surname><given-names>JP</given-names></name>
<name><surname>Abernethy</surname><given-names>AP</given-names></name>
<etal/></person-group>. <article-title>Prescribing in palliative care as death approaches</article-title>. <source>J Am Geriatr Soc</source> <year>2007</year>; <volume>55</volume>: <fpage>590</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr20-0269216312464263">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
<name><surname>To</surname><given-names>THM</given-names></name>
<name><surname>Abernethy</surname><given-names>AP</given-names></name>
</person-group>. <article-title>Prescribing at times of clinical transition in chronic or progressive diseases</article-title>. <source>Int J Gerontol</source> <year>2009</year>; <volume>3</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr21-0269216312464263">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dietz</surname><given-names>I</given-names></name>
<name><surname>Borasio</surname><given-names>GD</given-names></name>
<name><surname>Schneider</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Medical errors and patient safety in palliative care: a review of current literature</article-title>. <source>J Palliat Med</source> <year>2010</year>; <volume>13</volume>: <fpage>1469</fpage>–<lpage>1474</lpage>.</citation>
</ref>
<ref id="bibr22-0269216312464263">
<label>22.</label>
<citation citation-type="web"><article-title>Good practice in prescribing medicines – guidance for doctors</article-title>, <ext-link ext-link-type="uri" xlink:href="http://www.gmc-uk.org/guidance/ethical_guidance/prescriptions_faqs.asp#10">http://www.gmc-uk.org/guidance/ethical_guidance/prescriptions_faqs.asp#10</ext-link> (<year>2008</year>, <access-date>accessed 12 June 2012</access-date>).</citation>
</ref>
<ref id="bibr23-0269216312464263">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Von Elm</surname><given-names>E</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
<name><surname>Egger</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>J Clin Epidemiol</source> <year>2008</year>; <volume>61</volume>: <fpage>344</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr24-0269216312464263">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ansani</surname><given-names>N</given-names></name>
<name><surname>Branch</surname><given-names>R</given-names></name>
<name><surname>Fedutes-Henderson</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>United States medical practice summary: innovative off-label medication use</article-title>. <source>Am J Med Qual</source> <year>2006</year>; <volume>21</volume>: <fpage>246</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr25-0269216312464263">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toscani</surname><given-names>F</given-names></name>
<name><surname>Di Giulio</surname><given-names>P</given-names></name>
<name><surname>Campi</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Off-label prescriptions in Italian hospices: a national survey</article-title>. <source>J Pain Symptom Manage</source> <year>2009</year>; <volume>38</volume>: <fpage>365</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr26-0269216312464263">
<label>26.</label>
<citation citation-type="journal"><collab>Anon</collab>. <article-title>Use of approved drugs for unlabeled indications</article-title>. <source>FDA Drug Bull</source> <year>1982</year>; <volume>12</volume>: <fpage>4</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr27-0269216312464263">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shapiro</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Limiting physician freedom to prescribe a drug for any purpose: the need for FDA regulation</article-title>. <source>Northwest Uni Law Rev</source> <year>1979</year>; <volume>73</volume>: <fpage>801</fpage>–<lpage>872</lpage>.</citation>
</ref>
<ref id="bibr28-0269216312464263">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>DT</given-names></name>
<name><surname>Wynia</surname><given-names>MK</given-names></name>
<name><surname>Moloney</surname><given-names>RM</given-names></name>
<etal/></person-group>. <article-title>U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey</article-title>. <source>Pharmacoepidemiol Drug Saf</source> <year>2009</year>; <volume>18</volume>: <fpage>1094</fpage>–<lpage>1100</lpage>.</citation>
</ref>
<ref id="bibr29-0269216312464263">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gazarian</surname><given-names>M</given-names></name>
<name><surname>Kelly</surname><given-names>M</given-names></name>
<name><surname>McPhee</surname><given-names>JR</given-names></name>
<etal/></person-group>. <article-title>Off-label use of medicines: consensus recommendations for evaluating appropriateness</article-title>. <source>Med J Aust</source> <year>2006</year>; <volume>185</volume>: <fpage>544</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr30-0269216312464263">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
</person-group>. <article-title>Why don’t we do more rigorous clinical research so that we can stop experimenting on patients?</article-title> <source>J Palliat Med</source> <year>2010</year>; <volume>13</volume>: <fpage>636</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr31-0269216312464263">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gazarian</surname><given-names>M</given-names></name>
</person-group>. <article-title>Why are children still therapeutic orphans?</article-title> <source>Austr Presc</source> <year>2003</year>; <volume>26</volume>: <fpage>122</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr32-0269216312464263">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mack</surname><given-names>A</given-names></name>
</person-group>. <article-title>Examination of the evidence for off-label use of gabapentin</article-title>. <source>J Manag Care Pharm</source> <year>2003</year>; <volume>9</volume>: <fpage>559</fpage>–<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr33-0269216312464263">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>S</given-names></name>
<name><surname>Nunn</surname><given-names>AJ</given-names></name>
<name><surname>Fielding</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study</article-title>. <source>Acta Paediatr</source> <year>1999</year>; <volume>88</volume>: <fpage>965</fpage>–<lpage>968</lpage>.</citation>
</ref>
<ref id="bibr34-0269216312464263">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neubert</surname><given-names>A</given-names></name>
<name><surname>Dormann</surname><given-names>H</given-names></name>
<name><surname>Weiss</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients</article-title>. <source>Drug Saf</source> <year>2004</year>; <volume>27</volume>: <fpage>1059</fpage>–<lpage>1067</lpage>.</citation>
</ref>
<ref id="bibr35-0269216312464263">
<label>35.</label>
<citation citation-type="book"><collab>Anon</collab>. <source>Evidence of harm from off label or unlicensed medicines in children</source>. <publisher-loc>London</publisher-loc>: <publisher-name>European Medicines Agency (EMEA)</publisher-name>; <year>2004</year>.</citation>
</ref>
<ref id="bibr36-0269216312464263">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilkes</surname><given-names>M</given-names></name>
<name><surname>Johns</surname><given-names>M</given-names></name>
</person-group>. <article-title>Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions</article-title>. <source>PLoS Med</source> <year>2008</year>; <volume>5</volume>: <fpage>e223</fpage>.</citation>
</ref>
<ref id="bibr37-0269216312464263">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ansani</surname><given-names>N</given-names></name>
<name><surname>Sirio</surname><given-names>C</given-names></name>
<name><surname>Smitherman</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Designing a strategy to promote safe, innovative off-label use of medications</article-title>. <source>Am J Med Qual</source> <year>2006</year>; <volume>21</volume>: <fpage>255</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr38-0269216312464263">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blum</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Legal considerations in off-label medication prescribing</article-title>. <source>Arch Intern Med</source> <year>2002</year>; <volume>162</volume>: <fpage>1777</fpage>–<lpage>1779</lpage>.</citation>
</ref>
<ref id="bibr39-0269216312464263">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomadsen</surname><given-names>BR</given-names></name>
<name><surname>Heaton</surname><given-names>HT</given-names><suffix>2nd</suffix></name>
<name><surname>Jani</surname><given-names>SK</given-names></name>
<etal/></person-group>. <article-title>Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121</article-title>. <source>Med Phys</source> <year>2010</year>; <volume>37</volume>: <fpage>2300</fpage>–<lpage>2311</lpage>.</citation>
</ref>
<ref id="bibr40-0269216312464263">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>V</given-names></name>
</person-group>. <article-title>Off-label prescribing. Legal implications</article-title>. <source>J Legal Med</source> <year>1999</year>; <volume>20</volume>: <fpage>365</fpage>–<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr41-0269216312464263">
<label>41.</label>
<citation citation-type="journal"><collab>Anon</collab>. <article-title>Prescription drugs: FDA’s oversight of the promotion of drugs for off-label uses</article-title>. In: <collab>Office USGA</collab> (ed.) <source>Report to the ranking member, Committee on Finance, US Senate</source>, <year>2008</year>.</citation>
</ref>
<ref id="bibr42-0269216312464263">
<label>42.</label>
<citation citation-type="book"><collab>Anon</collab>. <source>Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices</source>. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>Food and Drug Administration</publisher-name>, <year>2009</year>.</citation>
</ref>
<ref id="bibr43-0269216312464263">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joseph</surname><given-names>JN</given-names></name>
<name><surname>Deaton</surname><given-names>D</given-names></name>
<name><surname>Ehsan</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going?</article-title> <source>J Health Life Sci Law</source> <year>2009</year>; <volume>2</volume>: <fpage>73</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr44-0269216312464263">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Healy</surname><given-names>D</given-names></name>
<name><surname>Nutt</surname><given-names>D</given-names></name>
</person-group>. <article-title>Prescriptions, licences and evidence</article-title>. <source>Psychiatr Bull</source> <year>1998</year>; <volume>22</volume>: <fpage>680</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr45-0269216312464263">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wertheimer</surname><given-names>A</given-names></name>
</person-group>. <article-title>Off-label prescribing of drugs for children</article-title>. <source>Curr Drug Saf</source> <year>2011</year>; <volume>6</volume>: <fpage>46</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr46-0269216312464263">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bright</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Positive outcomes through the appropriate use of off-label prescribing</article-title>. <source>Arch Intern Med</source> <year>2006</year>; <volume>166</volume>: <fpage>2554</fpage>–<lpage>2555</lpage>; author reply 5.</citation>
</ref>
<ref id="bibr47-0269216312464263">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joensuu</surname><given-names>H</given-names></name>
<name><surname>Roberts</surname><given-names>PJ</given-names></name>
<name><surname>Sarlomo-Rikala</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Effect of the Tyrosine Kinase Inhibitor STI571 in a patient with a Metastatic Gastrointestinal Stromal Tumor</article-title>. <source>N Engl J Med</source> <year>2001</year>; <volume>344</volume>: <fpage>1052</fpage>–<lpage>1056</lpage>.</citation>
</ref>
<ref id="bibr48-0269216312464263">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abernethy</surname><given-names>AP</given-names></name>
<name><surname>Currow</surname><given-names>DC</given-names></name>
<name><surname>Frith</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea</article-title>. <source>BMJ</source> <year>2003</year>; <volume>327</volume>: <fpage>523</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr49-0269216312464263">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edlin</surname><given-names>R</given-names></name>
<name><surname>Round</surname><given-names>J</given-names></name>
<name><surname>Hulme</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists</article-title>. <source>Br J Clin Pharmacol</source> <year>2010</year>; <volume>70</volume>: <fpage>350</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr50-0269216312464263">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fullerton</surname><given-names>CA</given-names></name>
<name><surname>Busch</surname><given-names>AB</given-names></name>
<name><surname>Frank</surname><given-names>RG</given-names></name>
</person-group>. <article-title>The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion</article-title>. <source>Med Care</source> <year>2010</year>; <volume>48</volume>: <fpage>372</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr51-0269216312464263">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oxman</surname><given-names>AD</given-names></name>
<name><surname>Thomson</surname><given-names>MA</given-names></name>
<name><surname>Davis</surname><given-names>DA</given-names></name>
<etal/></person-group>. <article-title>No magic bullets: a systematic review of 102 trials of interventions to improve professional practice</article-title>. <source>CMAJ</source> <year>1995</year>; <volume>153</volume>: <fpage>1423</fpage>–<lpage>1431</lpage>.</citation>
</ref>
<ref id="bibr52-0269216312464263">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flodgren</surname><given-names>G</given-names></name>
<name><surname>Parmelli</surname><given-names>E</given-names></name>
<name><surname>Doumit</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Local opinion leaders: effects on professional practice and health care outcomes</article-title>. <source>Cochrane Database Syst Rev</source> <year>2011</year>; <volume>8</volume>: <fpage>CD000125</fpage>.</citation>
</ref>
<ref id="bibr53-0269216312464263">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Todd</surname><given-names>J</given-names></name>
<name><surname>Davies</surname><given-names>A</given-names></name>
</person-group>. <article-title>Use of unlicensed medication in palliative medicine</article-title>. <source>Palliat Med</source> <year>1999</year>; <volume>13</volume>: <fpage>446</fpage>.</citation>
</ref>
<ref id="bibr54-0269216312464263">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>C</given-names></name>
<name><surname>Gilshenan</surname><given-names>K</given-names></name>
<name><surname>Hardy</surname><given-names>J</given-names></name>
</person-group>. <article-title>A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative care</article-title>. <source>Support Care Cancer</source> <year>2008</year>; <volume>16</volume>: <fpage>1397</fpage>–<lpage>1405</lpage>.</citation>
</ref>
<ref id="bibr55-0269216312464263">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>CD</given-names></name>
<name><surname>Hardy</surname><given-names>JR</given-names></name>
<name><surname>Gilshenan</surname><given-names>KS</given-names></name>
<etal/></person-group>. <article-title>Randomised controlled trials of palliative care – a survey of the views of advanced cancer patients and their relatives</article-title>. <source>Eur J Cancer</source> <year>2008</year>; <volume>44</volume>: <fpage>1820</fpage>–<lpage>1828</lpage>.</citation>
</ref>
<ref id="bibr56-0269216312464263">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>C</given-names></name>
<name><surname>Hardy</surname><given-names>J</given-names></name>
</person-group>. <article-title>What do palliative care patients and their relatives think about research in palliative care? – a systematic review</article-title>. <source>Support Care Cancer</source> <year>2010</year>; <volume>18</volume>: <fpage>905</fpage>–<lpage>911</lpage>.</citation>
</ref>
<ref id="bibr57-0269216312464263">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Largent</surname><given-names>EA</given-names></name>
<name><surname>Miller</surname><given-names>FG</given-names></name>
<name><surname>Pearson</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Going off-label without venturing off-course: evidence and ethical off-label prescribing</article-title>. <source>Arch Intern Med</source> <year>2009</year>; <volume>169</volume>: <fpage>1745</fpage>–<lpage>1747</lpage>.</citation>
</ref>
<ref id="bibr58-0269216312464263">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edersheim</surname><given-names>JG</given-names></name>
<name><surname>Stern</surname><given-names>TA</given-names></name>
</person-group>. <article-title>Liability associated with prescribing medications</article-title>. <source>Prim Care Companion J Clin Psychiatr</source> <year>2009</year>; <volume>11</volume>: <fpage>115</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr59-0269216312464263">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quill</surname><given-names>TE</given-names></name>
<name><surname>Holloway</surname><given-names>R</given-names></name>
</person-group>. <article-title>Time-limited trials near the end of life</article-title>. <source>JAMA</source> <year>2011</year>; <volume>306</volume>: <fpage>1483</fpage>–<lpage>1484</lpage>.</citation>
</ref>
<ref id="bibr60-0269216312464263">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abernethy</surname><given-names>AP</given-names></name>
<name><surname>Currow</surname><given-names>DC</given-names></name>
</person-group>. <article-title>Time-limited trials</article-title>. <source>JAMA</source> <year>2012</year>; <volume>307</volume>: <fpage>33</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr61-0269216312464263">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
<name><surname>Rowett</surname><given-names>D</given-names></name>
<name><surname>Doogue</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice</article-title>. <source>J Palliat Med</source> <year>2012</year>; <volume>15</volume>: <fpage>282</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr62-0269216312464263">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Price</surname><given-names>DW</given-names></name>
<name><surname>Raebel</surname><given-names>MA</given-names></name>
<name><surname>Conner</surname><given-names>DA</given-names></name>
<etal/></person-group>. <article-title>Pharmaceuticals from development to practice: learnings from an online curriculum</article-title>. <source>Am J Manag Care</source> <year>2009</year>; <volume>15</volume>: <fpage>e109</fpage>–<lpage>e114</lpage>.</citation>
</ref>
<ref id="bibr63-0269216312464263">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eguale</surname><given-names>T</given-names></name>
<name><surname>Winslade</surname><given-names>N</given-names></name>
<name><surname>Hanley</surname><given-names>JA</given-names></name>
<etal/></person-group>. <article-title>Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada</article-title>. <source>Drug Saf</source> <year>2010</year>; <volume>33</volume>: <fpage>559</fpage>–<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr64-0269216312464263">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landefeld</surname><given-names>CS</given-names></name>
<name><surname>Steinman</surname><given-names>MA</given-names></name>
</person-group>. <article-title>The neurontin legacy – marketing through misinformation and manipulation</article-title>. <source>N Engl J Med</source> <year>2009</year>; <volume>360</volume>: <fpage>103</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr65-0269216312464263">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Zee</surname><given-names>A</given-names></name>
</person-group>. <article-title>The promotion and marketing of OxyContin: commercial triumph, public health tragedy</article-title>. <source>Am J Public Health</source> <year>2009</year>; <volume>99</volume>: <fpage>221</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr66-0269216312464263">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hébert</surname><given-names>PC</given-names></name>
<name><surname>Stanbrook</surname><given-names>M</given-names></name>
</person-group>. <article-title>Indication creep: physician beware</article-title>. <source>CMAJ</source> <year>2007</year>; <volume>177</volume>: <fpage>697</fpage>.</citation>
</ref>
<ref id="bibr67-0269216312464263">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
<name><surname>Shelby-James</surname><given-names>TM</given-names></name>
<name><surname>Agar</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations</article-title>. <source>Support Care Canc</source> <year>2010</year>; <volume>18</volume>: <fpage>1571</fpage>–<lpage>1579</lpage>.</citation>
</ref>
<ref id="bibr68-0269216312464263">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walton</surname><given-names>SM</given-names></name>
<name><surname>Schumock</surname><given-names>GT</given-names></name>
<name><surname>Lee</surname><given-names>KV</given-names></name>
<etal/></person-group>. <article-title>Prioritizing future research on off-label prescribing: results of a quantitative evaluation</article-title>. <source>Pharmacotherapy</source> <year>2008</year>; <volume>28</volume>: <fpage>1443</fpage>–<lpage>1452</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>